Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol 2026 Jul;90(1):85-87
Date
09/16/2025
Pubmed ID
40954009DOI
10.1016/j.eururo.2025.09.003Scopus ID
2-s2.0-105018024297 (requires institutional sign-in at Scopus site)
10 CitationsAuthor List
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS
Author
Deepak Kilari MD Associate Professor in the Medicine department at Medical College of Wisconsin